NNNN (Anbio Biotechnology) EPS without NRI: $0.14 (TTM As of Dec. 2025)


NNNN Anbio Biotechnology NNNN
24 GF Score
Price $9.39
! 2 Warning Signs
View Full Analysis

What is Anbio Biotechnology EPS without NRI?

Anbio Biotechnology NNNN -12.41% 24 EPS without NRI is $0.14 as of Dec. 2025. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 662 Medical Devices & Instruments companies, Anbio Biotechnology ranks better than 71.45% on this metric.

Anbio Biotechnology's earnings per share without non-recurring items for the six months ended in Dec. 2025 was $0.06. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $0.14.

During the past 12 months, Anbio Biotechnology's average earnings per share (NRI) Growth Rate was 151.90% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 24.20% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Anbio Biotechnology's EPS without NRI or its related term are showing as below:

NNNN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 24.2   Med: 26.75   Max: 29.3
Current: 24.2

During the past 5 years, Anbio Biotechnology's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 29.30% per year. The lowest was 24.20% per year. And the median was 26.75% per year.

NNNN's 3-Year EPS without NRI Growth Rate is ranked better than
71.45% of 662 companies
in the Medical Devices & Instruments industry
Industry Median: 8.15 vs NNNN: 24.20

Anbio Biotechnology's EPS (Diluted) for the six months ended in Dec. 2025 was $0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15.

Anbio Biotechnology's EPS (Basic) for the six months ended in Dec. 2025 was $0.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15.


Anbio Biotechnology  (NAS:NNNN) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Anbio Biotechnology EPS without NRI Related Terms


Anbio Biotechnology EPS without NRI Historical Data

* Premium members only.

The historical data trend for Anbio Biotechnology's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anbio Biotechnology EPS without NRI Chart

Anbio Biotechnology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
0.03 0.07 0.01 0.05 0.14

Anbio Biotechnology Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only 0.00 0.09 -0.03 0.08 0.06

NNNN vs ANGO, OSUR, UTMD: EPS without NRI Comparison

For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anbio Biotechnology PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Anbio Biotechnology's PE Ratio without NRI falls into.


NNNN
24GF Score
Anbio Biotechnology NNNN
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anbio Biotechnology EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $0.14 mean?
Anbio Biotechnology (NNNN) has a EPS without NRI of $0.14 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Anbio Biotechnology and its competitors. According to the industry distribution chart, Anbio Biotechnology ranks #189 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 28.5%.
Is Anbio Biotechnology's EPS without NRI too high?
Anbio Biotechnology's current EPS without NRI is $0.14. The Medical Devices & Instruments industry median EPS without NRI is 8.15. Anbio Biotechnology's value of $0.14 is 98.3% below this industry median. Based on the distribution chart, Anbio Biotechnology ranks #189 out of 662 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's EPS without NRI compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #189 out of 662 companies for EPS without NRI. This puts Anbio Biotechnology in the upper half of its industry. The industry median EPS without NRI is 8.15. Anbio Biotechnology's value of $0.14 is 98.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.15, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current EPS without NRI of $0.14 is 98.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current EPS without NRI is $0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current EPS without NRI of $0.14. The current EPS without NRI is $0.14 and 98.3% below the Medical Devices & Instruments industry median of 8.15. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current EPS without NRI is $0.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anbio Biotechnology Business Description

Address Friedrich-Ebert-Anlage 35-37, Frankfurt am Main, HE, DEU, 60327
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score

Get the complete analysis for NNNN

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.39
Price